the swiss times
en_GB English
en_GB English de_DE German fr_FR French es_ES Spanish ar Arabic
the swiss times

Hemotune Secures CHF 14 Million for Clinical Trials

Hemotune Secures CHF 14 Million for Clinical Trials

Tue, Mar 26th 2024

Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.

Photo courtesy of Hemotune

Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.

The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.

Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.

Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.

Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.

The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.

Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.

Related Stories

Sunday 5th: Today’s Headlines & Reports
Thumbnail

5 May 2024

This Sunday in Switzerland: Kids skipping school and higher insurance salaries for execs. Health subsidies, Swiss...

Hochdorf: Shareholders To Change The Board
Thumbnail

3 May 2024

Hochdorf faces a significant board transformation as Newlat proposes six new candidates, predominantly Italian....

Federal Office of Police Cracks Down On Money Laundering
Thumbnail

8 May 2024

Switzerland's Federal Office of Police arrests key figures in a Europe-wide crackdown on money laundering activities...

Protests At ETH, Lausanne & Geneva: Students Take Direct Action
Thumbnail

7 May 2024

Protests advocating for Palestine surface at ETH Zurich, EPFL Lausanne, and the University of Geneva....

PSP Swiss Property: Strong Earnings
Thumbnail

7 May 2024

PSP Swiss Property boosts 2024 earnings, with Q1 net profits up 42% to CHF 81 million. Revised EBITDA forecast now at...

Julius Baer Sells Kairos
Thumbnail

3 May 2024

Julius Baer finalizes the sale of Kairos to Anima Holding, removing the Italian "problem subsidiary" from its portfolio....

Bern Riots: 11 Policeman Injured & Arrests
Thumbnail

6 May 2024

Unrest at Bern's Schützenmatte results in serious accusations by the regional police chief against rioters. ...

Stay in Touch

Noteworthy

Russian Assets Frozen In Switzerland Worth Less Now
Noteworthy
23 April 2024

Russian Assets Frozen In Switzerland Worth Less Now

Swiss Watch Exports Declined This March
Noteworthy
18 April 2024

Swiss Watch Exports Declined This March
the swiss times
A production of UltraSwiss AG, 6340 Baar, Switzerland

Quick Links

Home Privacy GTC Contact Us About Us
Copyright © 2024 UltraSwiss AG 2024 All rights reserved